synthorx Logo (WIPO, 07/10/2020)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark synthorx was filed as Figurative mark on 07/10/2020 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Armillary spheres, planetaria, astronomic orbits, atomic models, molecular models #Letters or numerals representing a human being, an animal, a plant, a heavenly body, a natural phenomenon or an object #Atomic models, molecular models, representations of human, animal or vegetal cells #Letters or numerals representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object
| Trademark form | Figurative mark |
| File reference | 1562572 |
| Countries | 
|
| Base trademark |
No. 88505851,
July 9, 2019
|
| Application date | July 10, 2020 |
| Expiration date | July 10, 2030 |
Trademark owner
11099 North Torrey Pines Road, Suite 190
La Jolla CA 92037
US
La Jolla CA 92037
US
Trademark representatives
31 rue de Fleurus
F-75006 Paris
FR
goods and services
05
Protein therapeutics expressed, prepared or manufactured
using a semi-synthetic organism, namely, pharmaceutical
preparations for use in immunology, oncology including
immuno-oncology, cardiovascular and metabolic diseases and
infectious diseases; protein therapeutics expressed,
prepared or manufactured using a semi-synthetic organism,
namely, proteins designed to deliver highly targeted
therapeutic modulation for patients suffering from a variety
of diseases, including cancer, autoimmune and inflammatory
diseases including transplantation and delayed-type
hypersensitivity, respiratory diseases, gastrointestinal
diseases, cardiovascular and metabolic diseases, pathogen
infections, musculoskeletal diseases, ophthalmologic and
dermatologic diseases, genitourinary diseases, degenerative
diseases and orphan diseases; protein therapeutics namely,
pharmaceutical preparations for use in immunology including
rheumatology, oncology including immuno-oncology,
pulmonology, gastroenterology, endocrinology, dermatology,
urology, gynecology including fertility, infectiology
including virology, ophthalmology, hepatology, neurology and
geriatrics; protein therapeutics, namely, proteins designed
to deliver highly targeted therapeutic modulation for
patients suffering from a variety of diseases, including
cancer and autoimmune disorders, cytokines, interferons,
tumor cell targeting and cytolytic agents, tolerogenic and
antiallergic factors, growth and differentiation factors,
hormones, replacement enzymes, coagulation factors, lipid
binding proteins, protein factors for manufacturing of
adoptive cell therapy products, anti-infectives, pain
killers, and tissue repair factors; modified protein to be
used in connection with a variety of therapeutic areas,
namely protein arrays for medical diagnostic purposes;
pharmaceutical preparations, namely, synthetic proteins for
use in immunology including rheumatology, oncology including
immuno-oncology, pulmonology, gastroenterology,
endocrinology, dermatology, urology, gynecology including
fertility, infectiology including virology, ophthalmology,
hepatology, neurology and geriatrics
42
Medical research; scientific research in the field of DNA;
pharmaceutical research and development; laboratory research
services in the field of pharmaceuticals; pharmaceutical
research in the field of protein therapeutics;
pharmaceutical research in the fields of immunology
including rheumatology, oncology including immuno-oncology,
pulmonology, gastroenterology, endocrinology, dermatology,
urology, gynecology including fertility, infectiology
including virology, ophthalmology, hepatology, neurology,
geriatrics, genetics and phenomics, pathology and forensics,
proteomics and veterinary medicine and diagnostics;
providing medical and scientific research information in the
field of pharmaceuticals and clinical trials; pharmaceutical
research using a semi-synthetic organism for use in drug
development; pharmaceutical research, namely, research
relating to synthetic proteins incorporating one or more
non-natural amino acids for improving pharmacological
properties; pharmaceutical research, namely, research
relating to synthetic proteins for use in connection with a
wide variety of therapeutic agents
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| May 19, 2022 | 2022/23 Gaz | MX | Rejection |
| May 5, 2022 | 2022/18 Gaz | TH | Rejection |
| March 30, 2022 | 2022/14 Gaz | CA | Rejection |
| March 10, 2022 | 2022/11 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| December 7, 2021 | 2021/49 Gaz | KR | Rejection |
| November 17, 2021 | 2021/46 Gaz | VN | Rejection |
| October 28, 2021 | 2021/43 Gaz | JP | Rejection |
| October 27, 2021 | 2021/43 Gaz | CH | Rejection |
| October 23, 2021 | 2021/43 Gaz | ID | Rejection |
| October 21, 2021 | 2021/42 Gaz | OA | Rejection |
| October 14, 2021 | 2021/41 Gaz | NO | Rejection |
| August 24, 2021 | 2021/34 Gaz | BR | Rejection |
| June 7, 2021 | 2021/25 Gaz | DZ | Rejection |
| April 15, 2021 | 2021/15 Gaz | EM | Rejection |
| April 5, 2021 | 2021/14 Gaz | GB | Rejection |
| March 23, 2021 | 2021/12 Gaz | CN | Rejection |
| March 14, 2021 | 2021/11 Gaz | PH | Rejection |
| March 3, 2021 | 2021/9 Gaz | AU | Rejection |
| March 1, 2021 | 2021/9 Gaz | RU | Rejection |
| July 10, 2020 | 2020/46 Gaz | US | Registration |
ID: 141562572